Evaluating surrogate marker information using censored data
From MaRDI portal
Cites work
- A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
- Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints
- Comparing biomarkers as principal surrogate endpoints
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Efficiency improvement in a class of survival models through model-free covariate incorporation
- Evaluating Candidate Principal Surrogate Endpoints
- scientific article; zbMATH DE number 837911 (Why is no real title available?)
- scientific article; zbMATH DE number 3092162 (Why is no real title available?)
- Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
- On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial
- Principal stratification in causal inference
- Robust estimation of the proportion of treatment effect explained by surrogate marker information
- Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data
- Surrogate measures and consistent surrogates
Cited in
(10)- Avoiding the surrogate paradox: an empirical framework for assessing assumptions
- Model-free approach to evaluate a censored intermediate outcome as a surrogate for overall survival
- Surrogate marker evaluation: a tutorial using R
- Robust evaluation of longitudinal surrogate markers with censored data
- On the role of surrogates in the efficient estimation of treatment effects with limited outcome data
- Validation of a longitudinal marker as a surrogate using mediation analysis and joint modeling: evolution of the PSA as a surrogate of the disease-free survival
- A general framework to assess complex heterogeneity in the strength of a surrogate marker
- Towards optimal use of surrogate markers to improve power
- Group sequential testing of a treatment effect using a surrogate marker
- Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events
This page was built for publication: Evaluating surrogate marker information using censored data
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6999275)
